Actively Recruiting
Comparing Linvoseltamab and Daratumumab Treatments for Adults with High-Risk Smoldering Multiple Myeloma
Led by Regeneron Pharmaceuticals · Updated on 2026-11-04
270
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying an experimental drug called linvoseltamab compared to another drug, daratumumab, in adults with Smoldering Multiple Myeloma SMM who have a high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the progression to multiple myeloma better than daratumumab. The study also looks at side effects, drug levels in the blood, and whether the body makes antibodies against the study drug. Participants are randomly assigned to receive either linvoseltamab or daratumumab, both administered according to the study protocol. The trial follows participants for up to five years to assess clinical and biochemical progression-free survival and other outcomes. Additional measures include response rates, adverse events, quality of life, and antibody presence against linvoseltamab. During the study, participants will undergo regular evaluations including clinical assessments and laboratory tests to monitor disease status, drug levels, and side effects. Quality of life questionnaires and other patient-reported outcomes will be collected over several years. Safety and response will be closely monitored throughout the trial, which may last up to nine years in total for long-term outcomes.
CONDITIONS
Brief Title
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here